Consequently, this study aimed to use Raji tumor cells and mouse models to investigate the role of melatonin as an immunomodulatory compound in CD19-targeting CAR T-cell therapy, thereby providing valuable insights into improving treatment protocols and ultimately enhancing patient outcomes. This evidence concerns the gene CD19 and neoplasm.